^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PIGF inhibitor

    Related drugs:
    1m
    AFLIWEST: Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Eylea (aflibercept intravitreal)
    1m
    THAMES: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P1/2, N=388, Completed, Genentech, Inc. | Trial completion date: Apr 2027 --> Jun 2026 | Trial primary completion date: Apr 2027 --> May 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    1m
    A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P3, N=304, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    2ms
    Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=33, Completed, Sam Chun Dang Pharm. Co. Ltd. | Not yet recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    2ms
    AVT29-GL-C01: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema (2025-522231-34-00)
    P2/3, N=172, Recruiting, Alvotech Swiss AG | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    2ms
    A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P3, N=304, Not yet recruiting, Amgen
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema (clinicaltrials.gov)
    P=N/A, N=3000, Active, not recruiting, Bayer | Trial primary completion date: Mar 2026 --> Jul 2027
    Trial primary completion date • Real-world evidence
    |
    Eylea (aflibercept intravitreal)
    2ms
    A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity) (clinicaltrials.gov)
    P=N/A, N=75, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    3ms
    ALVOEYE-HD: Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=256, Recruiting, Alvotech Swiss AG | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    3ms
    Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER). (clinicaltrials.gov)
    P3, N=210, Recruiting, King's College Hospital NHS Trust | N=81 --> 210
    Enrollment change • Head-to-Head
    |
    Eylea (aflibercept intravitreal)
    3ms
    THAMES: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P1/2, N=546, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    3ms
    Target Trial Emulation Framework for Comparing Early Efficacy of Faricimab and Aflibercept In the Treatment of Patients With Neovascular Age-Related Macular Degeneration With Pigment Epithelium Detachment (ChiCTR2600118980)
    P=N/A, N=97, Zhongshan Hospital, Fudan University; Zhongshan Hospital Fudan University
    New trial
    |
    Eylea (aflibercept intravitreal)